Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study

G. Zanetfa, C. Leventis, S. Lo Monico, F. Landoni, M. Marzola, C. Mangioni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirty patients with histologically proven recurrent or persistent squamous cell cervical carcinoma were treated with chemotherapy, consisting of a combination of bleomycin, ifosfamide and cis-platin (BIP). All patients were evaluable for response. An objective response was seen in nine of the 30 patients (30%): complete in two (6.7%) and partial in the other seven (23.3%). A total of 39 tumor sites was treated: five responses were observed in 26 irradiated areas (19%), whereas seven responses were observed in 13 nonirradiated areas (53.8%). Side-effects were mainly nausea, vomiting, alopecia, myelosupression, fever and impaired renal function. Encephalopathy was recorded in four patients (severe in one). No patient died from the toxic effects of chemotherapy. The results indicate that BIP is an active combination in recurrent and advanced cervical carcinoma, with acceptable toxicity; however, this combination failed to prove any superiority over other single or multidrug treatments proposed in the last decade.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume5
Issue number1
Publication statusPublished - 1995

Fingerprint

Ifosfamide
Bleomycin
Uterine Cervical Neoplasms
Prospective Studies
Drug Therapy
Poisons
Alopecia
Brain Diseases
Nausea
Vomiting
Squamous Cell Carcinoma
Fever
Carcinoma
Kidney
Neoplasms

Keywords

  • Cervical cancer
  • Chemotherapy
  • Gynecologic cancer
  • Ifosfamide

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Zanetfa, G., Leventis, C., Lo Monico, S., Landoni, F., Marzola, M., & Mangioni, C. (1995). Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. International Journal of Gynecological Cancer, 5(1), 56-60.

Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. / Zanetfa, G.; Leventis, C.; Lo Monico, S.; Landoni, F.; Marzola, M.; Mangioni, C.

In: International Journal of Gynecological Cancer, Vol. 5, No. 1, 1995, p. 56-60.

Research output: Contribution to journalArticle

Zanetfa, G, Leventis, C, Lo Monico, S, Landoni, F, Marzola, M & Mangioni, C 1995, 'Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study', International Journal of Gynecological Cancer, vol. 5, no. 1, pp. 56-60.
Zanetfa, G. ; Leventis, C. ; Lo Monico, S. ; Landoni, F. ; Marzola, M. ; Mangioni, C. / Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. In: International Journal of Gynecological Cancer. 1995 ; Vol. 5, No. 1. pp. 56-60.
@article{a191e2f8b8654a90a7ce81fadfdf9ef5,
title = "Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study",
abstract = "Thirty patients with histologically proven recurrent or persistent squamous cell cervical carcinoma were treated with chemotherapy, consisting of a combination of bleomycin, ifosfamide and cis-platin (BIP). All patients were evaluable for response. An objective response was seen in nine of the 30 patients (30{\%}): complete in two (6.7{\%}) and partial in the other seven (23.3{\%}). A total of 39 tumor sites was treated: five responses were observed in 26 irradiated areas (19{\%}), whereas seven responses were observed in 13 nonirradiated areas (53.8{\%}). Side-effects were mainly nausea, vomiting, alopecia, myelosupression, fever and impaired renal function. Encephalopathy was recorded in four patients (severe in one). No patient died from the toxic effects of chemotherapy. The results indicate that BIP is an active combination in recurrent and advanced cervical carcinoma, with acceptable toxicity; however, this combination failed to prove any superiority over other single or multidrug treatments proposed in the last decade.",
keywords = "Cervical cancer, Chemotherapy, Gynecologic cancer, Ifosfamide",
author = "G. Zanetfa and C. Leventis and {Lo Monico}, S. and F. Landoni and M. Marzola and C. Mangioni",
year = "1995",
language = "English",
volume = "5",
pages = "56--60",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study

AU - Zanetfa, G.

AU - Leventis, C.

AU - Lo Monico, S.

AU - Landoni, F.

AU - Marzola, M.

AU - Mangioni, C.

PY - 1995

Y1 - 1995

N2 - Thirty patients with histologically proven recurrent or persistent squamous cell cervical carcinoma were treated with chemotherapy, consisting of a combination of bleomycin, ifosfamide and cis-platin (BIP). All patients were evaluable for response. An objective response was seen in nine of the 30 patients (30%): complete in two (6.7%) and partial in the other seven (23.3%). A total of 39 tumor sites was treated: five responses were observed in 26 irradiated areas (19%), whereas seven responses were observed in 13 nonirradiated areas (53.8%). Side-effects were mainly nausea, vomiting, alopecia, myelosupression, fever and impaired renal function. Encephalopathy was recorded in four patients (severe in one). No patient died from the toxic effects of chemotherapy. The results indicate that BIP is an active combination in recurrent and advanced cervical carcinoma, with acceptable toxicity; however, this combination failed to prove any superiority over other single or multidrug treatments proposed in the last decade.

AB - Thirty patients with histologically proven recurrent or persistent squamous cell cervical carcinoma were treated with chemotherapy, consisting of a combination of bleomycin, ifosfamide and cis-platin (BIP). All patients were evaluable for response. An objective response was seen in nine of the 30 patients (30%): complete in two (6.7%) and partial in the other seven (23.3%). A total of 39 tumor sites was treated: five responses were observed in 26 irradiated areas (19%), whereas seven responses were observed in 13 nonirradiated areas (53.8%). Side-effects were mainly nausea, vomiting, alopecia, myelosupression, fever and impaired renal function. Encephalopathy was recorded in four patients (severe in one). No patient died from the toxic effects of chemotherapy. The results indicate that BIP is an active combination in recurrent and advanced cervical carcinoma, with acceptable toxicity; however, this combination failed to prove any superiority over other single or multidrug treatments proposed in the last decade.

KW - Cervical cancer

KW - Chemotherapy

KW - Gynecologic cancer

KW - Ifosfamide

UR - http://www.scopus.com/inward/record.url?scp=0028908526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028908526&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028908526

VL - 5

SP - 56

EP - 60

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -